FDA approves Opdivo in joint Cabometyx for the treatment of advanced renal cell carcinoma

The U.S. Food and Drug Administration (FDA) said recently that it has approved a joint first-line treatment for patients with advanced renal cell carcinoma (RCC) using the anti-PD-1 antibody Opdivo (nivolumab) and Exelixis' tyrosine kinase inhibitor Cabozantinib.
decision was supported by data from the CheckMate-9ER III trial, which evaluated the effectiveness of Opdivo in previously untreated late-stage or metastasis RCC patients compared to Pfizer's Sunitinib.
, published in the European Society of Medical Oncology (ESMO) in 2020, showed that after a medium follow-up of 18.1 months, the progress-free survival of patients in the Opdivo combined Cabometyx group was 16.6 months, while the progress-free survival of patients in the Sutt group was only 8.3 months.
, Opdivo and Cabometyx also significantly reduced the risk of death by 40 percent compared to using Sutt alone.
kidney cell carcinoma (RCC) is a type of kidney cancer that is produced in small mucous membranes in the kidneys.
, a tumor grows in a single form, but sometimes more than one tumor may appear in one or both kidneys.
cancer is the most common type of kidney cancer in adults and tends to have the greatest impact on men between the ages of 50 and 70.